Search
ARC is a global network of collaborators committed to reducing the burden of RHD in our lifetime.
Aims: To determine the minimum inhibitory concentrations of penicillin G against a representative collection of Strep A strains; and to evaluate the impact of penicillin G concentration and size of bacterial inoculum on the prophylactic effect for Strep A strains
In this study we will use new methods to comprehensively test immune responses in blood samples from people with ARF (diagnosed using the Jones Criteria) and healthy volunteers at Royal Darwin and from Auckland Hospital, New Zealand, to find any unique signature that reliably identifies ARF.
‘Improving Health Outcomes in the Tropical North’ will strengthen partnerships with key research institutions across the NT, Qld, WA, NSW, Vic and SA, by undertaking an integrated research agenda that will help close the gap in Indigenous health disadvantage, protect the north from emerging infectious threats and
This work will be undertaken in collaboration with The Kids Research Institute Australia and Australian based research teams to better understand how Penicillin works in Māori and Pacific children/teens who receive monthly BPG injections.
This project aimed to identify the primordial determinants of RHD to inform prevention strategies.
We are conducting a genetic study to better understand why some people are susceptible to RHD and others are not.
The main objective of the study is to establish a comprehensive register of congenital and acquired heart disease in WA with accurate re-classification of all cases through Princess Margart Hospital using international diagnostic codes.
This project aims to develop a longer acting formulation of penicillin, such that frequency of the injection can be increased up to 3-6 months.
The key objective of this study is to collect data about patient and clinician preferences about reformulations.